| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Trebananib | AMG-386; 20060439 | Phase 2 Clinical | Amgen Inc, Takeda Pharmaceutical Co Ltd | Adenocarcinoma, Clear Cell; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hemangiosarcoma; Kidney Diseases; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Renal Insufficiency; Sarcoma; Sarcoma, Endometrial Stromal; Solid tumours; Uterine Neoplasms | 詳細 |
| EXG102-031 | EXG102-031; EXG102-031 (rAAV-based gene therapy) | Phase 2 Clinical | Exegenesis Bio Inc | Macular Degeneration; Wet Macular Degeneration | 詳細 |
| XMVA09 | XMVA-09; XMVA-09 (AAV载体基因治疗药物) | Phase 2 Clinical | Starry Gene | Diabetic macular oedema; Wet Macular Degeneration | 詳細 |
| ASKG-712 | ASKG-712; AM-712; VIS-101 | Phase 2 Clinical | Askgene Pharma | Diabetic macular oedema; Geographic Atrophy; Macular Degeneration; Wet Macular Degeneration | 詳細 |
| Y-400 | Y-400 | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Diabetic macular oedema; Macular Degeneration; Wet Macular Degeneration | 詳細 |
| Zifibancimig | RO-7250284 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Macular Degeneration | 詳細 |
| BI-836880 | BI-836880 | Phase 2 Clinical | Ablynx Nv | Neoplasms; Wet Macular Degeneration | 詳細 |
| Vanucizumab | RG-7221; RO-5520985; B800Z06O8K (UNII code) | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Colorectal Neoplasms; Neoplasms; Solid tumours | 詳細 |
| IBI-324 | IBI-324; OLN324 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Diabetic macular oedema; Macular Degeneration | 詳細 |
| EB-105 | EB-105 | Phase 1 Clinical | Eluminex Biosciences (Suzhou) Ltd | Diabetic macular oedema; Diabetic Retinopathy | 詳細 |
| Bispecific antibody for ocular fundus(kexing) | GB-10; GB10 | Phase 1 Clinical | Shandong Kexing Bio-Products Co Ltd | Eye Diseases; Macular Degeneration; Wet Macular Degeneration | 詳細 |
| RG-6120 | RG-6120 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Macular Degeneration | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Faricimab | RO-6867461; RG-7716 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | Vabysmo, 罗视佳 | United States | Wet Macular Degeneration; Diabetic macular oedema | Genentech Inc | 2022-01-28 | Choroid Diseases; Choroidal Neovascularization; Diabetes Complications; Diabetes Mellitus; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Myopia; Polypoidal choroidal vasculopathy; Retinal Diseases; Retinal Vein Occlusion; Vision Disorders; Wet Macular Degeneration | 詳細 |
